August 2026's Asian Undervalued Small Caps With Insider Buying

As August 2026 unfolds, the Asian markets are navigating a landscape marked by resilient business activity and geopolitical developments that have bolstered investor sentiment. With key indices like the S&P MidCap 400 and Russell 2000 showing robust gains, small-cap stocks in Asia are drawing attention, particularly those with insider buying—a potential indicator of confidence in their undervalued status amidst current market dynamics.

Top 10 Undervalued Small Caps With Insider Buying In Asia

Name	PE	PS	Discount to Fair Value	Value Rating
Security Bank	4.5x	0.9x	19.14%	★★★★★☆
East West Banking	2.7x	0.7x	36.95%	★★★★★☆
Paragon Care	NA	0.1x	36.95%	★★★★★☆
SHAPE Australia	21.4x	0.5x	25.06%	★★★★☆☆
ReadyTech Holdings	169.5x	1.7x	40.06%	★★★★☆☆
Apex Mining	8.5x	3.5x	-43.49%	★★★☆☆☆
Natural Food International Holding	11.4x	1.2x	8.67%	★★★☆☆☆
China XLX Fertiliser	12.6x	0.5x	42.25%	★★★☆☆☆
Chinasoft International	23.3x	0.4x	-2917.79%	★★★☆☆☆
BCI Minerals	NA	365.1x	8.64%	★★★☆☆☆

Click here to see the full list of 54 stocks from our Undervalued Asian Small Caps With Insider Buying screener.

Underneath we present a selection of stocks filtered out by our screen.

Navigator Global Investments (ASX:NGI)

Simply Wall St Value Rating: ★★★★★☆

Overview: Navigator Global Investments is an asset management company primarily engaged in providing investment solutions and services through its Lighthouse subsidiary, with a market capitalization of approximately A$0.34 billion.

Operations: Lighthouse contributes significantly to revenue, with recent figures showing $150.39 million. The company's net profit margin has shown notable fluctuations, reaching as high as 1.02% in late 2024 and early 2025 before decreasing to 0.35% by the end of that year. Operating expenses and non-operating income have varied over time, impacting overall profitability metrics consistently throughout the periods observed.

PE: 24.1x

Navigator Global Investments, a key player in the Asian investment landscape, showcases insider confidence with recent share purchases between March and July 2026. Despite its small size, the company is poised for growth with earnings projected to rise by 38% annually. However, it relies entirely on external borrowing for funding, which adds risk. Profit margins have dipped to 34.6%, influenced by one-off items. These dynamics paint a complex picture of potential and caution for investors considering this stock in Asia's market.

• Dive into the specifics of Navigator Global Investments here with our thorough valuation report.

• Explore historical data to track Navigator Global Investments' performance over time in our Past section.

Orora (ASX:ORA)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Orora operates in the packaging industry, focusing on its Orora Cans and Global Glass segments, with a market cap of A$3.56 billion.

Operations: The company generates revenue primarily from its Orora Cans and Global Glass segments, with the latter contributing A$1.34 billion. The cost of goods sold (COGS) significantly impacts its financial results, with recent figures showing a gross profit margin of 23.27%. Operating expenses are another notable component, including general and administrative expenses which recently amounted to A$226.6 million.

PE: 14.6x

Orora, a packaging solutions provider in Asia, recently reported sales of A$2.23 billion for the year ending June 30, 2026, up from A$2.09 billion the previous year. Despite this increase in revenue, they faced a net loss of A$616.6 million compared to last year's net income of A$973.1 million due to significant one-off items impacting results. The company's reliance on external borrowing poses higher financial risks; however, insider confidence is evident with recent share purchases by management over the past six months suggesting potential future growth despite current challenges.

• Click here and access our complete valuation analysis report to understand the dynamics of Orora.

• Learn about Orora's historical performance.

Shanghai Haohai Biological Technology (SEHK:6826)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Shanghai Haohai Biological Technology is engaged in the production and sale of biologics, with a focus on medical hyaluronic acid, and has a market capitalization of CN¥13.45 billion.

Operations: The company's revenue is primarily derived from the production and sale of biologics, particularly medical hyaluronic acid, with a recent quarterly revenue of CN¥2.40 billion. The gross profit margin has shown a gradual decline over several periods, reaching 68.29% as of the latest data point. Operating expenses are substantial, driven by sales and marketing costs along with research and development investments.

PE: 13.9x

Shanghai Haohai Biological Technology, a smaller player in Asia's market, is catching attention for its potential growth. Despite recent executive changes with Dr. Hou stepping down and Mr. Wu taking the helm, insider confidence remains strong with significant share purchases over the past year. The company announced a dividend of RMB 0.6 per share for 2025, highlighting shareholder returns amidst profit margin challenges—9.8% down from last year's 15.6%. Future earnings are projected to grow at an impressive rate of 23.52% annually, suggesting promising prospects despite reliance on external borrowing for funding needs.

• Click here to discover the nuances of Shanghai Haohai Biological Technology with our detailed analytical valuation report.

• Gain insights into Shanghai Haohai Biological Technology's historical performance by reviewing our past performance report.

Where To Now?

• Unlock our comprehensive list of 54 Undervalued Asian Small Caps With Insider Buying by clicking here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com